Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2005-02-15
2005-02-15
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C530S300000, C530S825000, C530S826000, C530S806000, C530S807000, C530S350000, C424S184100, C424S197110, C424S234100, C424S236100, C424S247100, C424S210100, C424S209100, C424S227100, C424S831000, C424S832000, C514S002600
Reexamination Certificate
active
06855321
ABSTRACT:
The invention relates to polyepitope carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are use useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines arm particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years.
REFERENCES:
patent: 4695624 (1987-09-01), Marburg et al.
patent: 4882317 (1989-11-01), Marburg et al.
patent: 4902506 (1990-02-01), Anderson et al.
patent: 5651971 (1997-07-01), Lees
patent: 5728385 (1998-03-01), Classen
patent: 0270295 (1988-08-01), None
patent: 0 429 816 (1991-06-01), None
patent: WO 8605790 (1986-10-01), None
patent: WO 9603144 (1996-02-01), None
patent: WO 9843677 (1998-10-01), None
Pesters et al. Infect. Immun. 60: 1826-1833, 1992.*
Falugi et al. Eur. J. Immunol. 31: 3816-3824, 2001.*
Jennings et al. In: Seminars in Infectious Disease. (Ed) Weinstein et al. vol. IV, Chapter 34, pp. 247-253, 1982.*
Agadjanyan et al.,“Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus”,Nature Biotechnol,15:547-551,(1997).
Ahlers et al., “Construction of an HIV-1 Peptide Vaccine Containing a Multideterminant Helper Peptide Linked to a V3 Loop Peptide 18 Inducing Strong Neutralizing Antibody Responses in Mice of Multiple MHC Haplotypes after Two Immunizations”,J. of Immun., 150(12),5647-5665,(1993).
Andreoni et al., “Vaccination and the Role of Capsular Polysaccharide Antibody in Prevention of Recurrent Meningococcal Disease in Late Complement Component-Deficient Individuals”,J. Infect. Dis., 168:227-231,(1993).
Anderson et al., “Antibody Responses toHaemophilus influenzaeType b and Diphtheria Toxin Induced by Conjugates of Oligosaccharides of the Type b Capsule with the Nontoxic Protein CRM”,Infect. Immun., 39(1):233-238,(1983).
Anderson et al., “Immunization of 2-month-old infants with protein-coupled oligosaccharides derived from the capsule of Haemophilus influenzae type b”,J. Pediatrics,107:346-351,(1985).
Anderson et al., “Immunogens Consisting of Oligosaccharides from the Capsule ofHaemophilus influenzaeType b Coupled to Diphtheria Toxoid or the Toxin Protein CRM197”,J. Clin. Invest.,76:52-59,(1985).
Bixler et al., “Synthetic Peptide Representing a T-Cell Epitope of CRM197 Substitutes as Carrier Molecule in a Haemophilus Influenzae Type b (HIB) Conjugate Vaccine”,Advances in Exper. Med. Bio.,251:175-180,(1989).
Chang et al., “Anergy in Immature B Lymphocytes Differential Responses to Receptor-Mediated Stimulation and T Helper Cells”,J. Immun., 147(3), 750-756, (1991).
Constantino et al., “Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C”,Vaccine,10(10), 691-698, (1992).
Dick et al., “Glycoconjugates of Bacterial Carbohydrate Antigens”,Conjugate Vaccines,10:48-114, (1989).
Etlinger et al., “Use of Prior Vaccinations for the Development of New Vaccines”,Science,249:423-425, (1990).
Goldblatt et al., “Role of Cell Wall Polysaccharide in the Assessment of IgG Antibodies to the Capsular Polysaccharides ofStreptococcus pneumoniaein Childhood”,J. Infect. Dis.,166:632-634, (1992).
Good et al., “Construction of Synthetic Immunogen: Use of New T-Helper Epitope on Malaria Circumsporozoite Protein”,Science,235:1059-1062, (1987).
Grandoff et al., “Effect of immunity to the carrier protein on antibody responses toHaemophilus influenzaetype b conjugate vaccines”,Vaccine,11(1):546-551, (1993).
Grandoff et al., “Induction of Immunologic Memory in Infants Primed with Haemophilus influenzae Type b Conjugate Vaccines”,J. Infect. Dis.,168:663-671, (1993).
Hayward et al., “Induction of Plasma Cell Differentiation of Human Fetal Lymphocytes: Evidence For Functional Immaturity of t and b Cells”,J. Immun.,119:(4):1213-1217, (1977).
Holmes et al., “The Biology ofHaemophilus influenzaeType b Vaccination Failure”,J. Infect. Dis., 165:5121-5128, (1992).
Insel et al., “Oligosaccharide-Protein Conjugate Vaccines Induce and Prime for Oligoclonal IgC Antibody Responses to theHaemophilus influenzaeby Capsular Polysaccharide in Human Infants”,J. Exp. Med., 163:262-269, (1986).
Ishioka et al., “MHC Interaction and T Cell Recognition of Carbohydrates and Glycopeptides”,J. Immun.,148:2446-2451, (1992).
Jennings et al., “Immunochemistry of Groups A, B, and C Meningococcal Polysaccharide-Tetanus Toxiod Conjugates”,J. Immun., 127:1011-1018, (1981).
Kaliyaperumal et al., “Carrier-induced epitope-specific regulation and its bypass in a protein-protein conjugate”,Eur. J. Immunol.,25:3375-3380, (1995).
Konadu et al., “Synthesis, Characterization, and Immunological Properties in Mice of Conjugates Composed of Detoxified Lipopolysaccharide ofSalmonella paratyphiA Bound to Tetanus Toxoid, with Emphasis on the Role of O Acetyls”,Infect. Immun.,64(7):2709-2715, (1996).
Konen-Waisman et al., “Self amd Foreign 60-Kilodalton Heat Shock Protein T Cell Epitope Peptides Serve As Immunogenic Carriers for a T Cell-Independent Sugar Antigen”,J. Immunol., 154:5977-5985, (1995).
Kumar et al., ““Universal” T Helper Cell Determinants Enhance Immunogenicity of aPlasmodium falciparumMerozoite Surface Antigen Peptide”,j. Immunol., 148:1499-1505, (1992).
Leclerc et al., “A synthetic vaccine constructed by copolymerization of B and T cell determinants”,Eur. J. Immunol., 17:269-273, (1987).
Lett et al., “Immunogenicity of Polysaccharides Conjugated to Peptides Containing T—and B-Cell Epitopes”,Infect. Immun.,62(3):785-792, (1994).
Liptak et al., “Decline of pediatric admissions withHaemophilus influenzaetype b in New York State, 1982 through 1993: Relation to immunizations”,J. Pediatrics,130:923-930, (1997).
Lucas et al., “Functional Differences in Idiotypically Defined IgG1 Anti-Polysaccharide Antibodies Elicited by Vaccination with Haemophilus influenzae Type B Polysaccharide-Protine Conjugates”,J. Immunol., 154:4195-4202, (1995).
McNamara et al., “Monoclonal Idiotope Vaccine AgainstStreptococcus pneumoniaeInfection”,Science,226:1325-1326, (1984).
Marburg et al., “Bimolecular Chemistry of Macromolecules: Synthesis of Bacterial Polysaccharide Conjugates withNeisseria meningitidisMembrane Protein”,J. Am. Chem.,108:5282-5287, (1986).
Moxon et al., “The Role of Bacterial Polysaccharide Capsules as Virulence Factors”,Curr. Top. Microbiol. Immunol.,150:65-85, (1990).
Panina-Bordignon et al., “Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells”,Eur. J. Immunol.,19:2237-2242, (1989).
Robbins et al., “Prevention of Systemic Infections, Especially Meningitis, Caused by Haemophilus influenzaeType b”,JAMA,276:1181-1185, (1996).
Sad et al., “Bypass of carrier-induced epitope-specific suppression using a T-helper epitope”,Immunol.,76:599-603, (1992).
Santosham M., “Prevention ofHaemophilus influenzaetype b disease”,Vaccine,11(1):552-557, (1993).
Schneerson et al., “Preparation, Characterization, and Immunogenicity of Haemophilus Influenzae Type b Polysaccharide-Protein Conjugates”,J. Exp. Med.,152:361-376, (1980).
Schneerson et al., “Quantitative and Qualitative Analyses of Serum Antibodies Elicited in Adults byHaemophilus influenzaeType b and Pneumococcus Type 6A Capsular Polysaccharide-Tetanus Toxoid Conjugates”,Inf. Immun.,52(2):519-528, (1986).
Sidman et al., “Receptor-mediated inactivation of early B lymphocytes”,Nature, 257:149-151, (1975).
Tunkel et al., “Pathogenesis and Pathophysiology of Bacterial Meningitis”,Clin. Microbio.,6(
Grandi Guido
Rappuoli Rino
Blackburn Robert P.
Chiron S.r.l.
Devi S.
Hale Rebecca M.
Robins Roberta L.
LandOfFree
Polyepitope carrier protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyepitope carrier protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyepitope carrier protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3468899